News

Graduate Student Internship Opportunities as GSK

2016 Heart Failure & Muscle Metabolism DPU Chemistry Co-Op positions

Gsk Logo Vig Orange Gray

The Heart Fail Failure and Muscle Metabolism Discovery Performance Units are offering full-time, 12-month co-op positions located at our Upper Merion campus in Pennsylvania. The primary focus of the placement will be the chemical synthesis of organic molecules to produce novel drug candidates, however as a member of our multi-disciplinary team you will also gain insight into the broader aspects of the drug discovery process. This is an excellent opportunity to extend your skill set in preparation for securing employment post-graduation.…

Read More

Ara Parseghian Medical Research Fund launches at Notre Dame

Marcia Christy Michael Parseghian

Building on the partnership that the University of Notre Dame formed with the Ara Parseghian Medical Research Foundation in 2010, the University has now established the Ara Parseghian Medical Research Fund and is moving the administrative functions and granting process of the foundation from Tucson, Arizona, to Notre Dame.

Through this partnership, the Parseghian family will continue their fight to find a cure or treatment for Niemann-Pick Type C (NPC) disease and will continue to help fundraise and support researchers around the world.

Read More

Ebola Research at Notre Dame, IU School of Medicine Funded by Indiana CTSI

The Indiana Clinical and Translational Sciences Institute (CTSI) has provided support for Olaf Wiest, University of Notre Dame professor of chemistry and biochemistry, and Robert Stahelin, Indiana University School of Medicine associate professor of biochemistry and molecular biology and adjunct associate professor of chemistry and biochemistry at Notre Dame, through the Notre Dame-CTSI Project Development Team.

Read More

Warren Center highlighted during NDday

The Warren Family Research Center for Drug Discovery and Development will be highlighted during the 10am hour, Monday, April 25th, live streaming NDday fundraising event. Please consider supporting the Warren Center during this opportunity.  All funds go directly to support laboratory research including our collaboration with the Grace Science Foundation

Read More

Second Chance Grant Funding

Give Your Application a Second Chance With OnPAR

If your meritorious application misses NIH's payline, a new private-public partnership pilot called Online Partnership to Accelerate Research (OnPAR) could offer a second chance to receive funding.

How OnPAR Helps

Onpar

Read More

Rare Disease Day and Rare Disease Research within the Warren Center

logo_rare_disease_day

 

Rare Disease Day takes place annually on the last day of February. Rare Disease Day’s goal is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients. Warren Center researchers have a rich history in rare disease therapeutic research and a few examples are summarized below.…

Read More

New avenues found for treatment of pathogen behind diseases including fasciitis, toxic shock syndrome

Scanning electron micrograph of red blood cell hemolysis by the Streptolysin S producing Group A Streptococcus. Credit: Shaun Lee, Dustin Higashi

One bacterial pathogen is responsible for a range of diseases, from pharyngitis and impetigo to more severe diagnoses such as toxic shock syndrome and necrotizing fasciitis (flesh eating disease), a serious bacterial skin infection that spreads quickly and kills the body’s soft tissue. The pathogen, known as Group A Streptococcus, remains a global health burden with an estimated 700 million cases reported annually, and more than half a million deaths due to severe infections.

Read More

CTSI Funding Opportunity for Early Stage Commercialization in Diagnostics and Therapeutics Development

SUBMISSION DEADLINE - THURSDAY, OCTOBER 01, 2015 (5:00 PM).

A common critical gap in commercialization of technologies originating from the academic labs is the funding necessary to develop a robust commercialization relevant data package to reduce the risk of investment in early stage technologies. The Indiana CTSI and Indiana University School of Medicine through the office of the Associate Dean for Entrepreneurship and its Industry Collaboration Portal (ICP), are partnering with the newly created Indiana Center for Biomedical Innovation (ICBI) at IU Health to help fill this critical gap through a new support program, Technology Enhancement Awards (TEA), for early stage technologies. The technology may already reside in a start-up company or a clear plan exists to place it into a start-up. The New Program will partner with the highly successful SPARK program at Stanford University.…

Read More

New Funding Opportunity to Support Pre-clinical Assays

Drug Development Services through the Molecular Therapeutics Program

SUBMISSION DEADLINE: October 15, 2015

The Molecular Therapeutics Program, a part of the Indiana Clinical and Translational Sciences Institute, has established a service agreement with Covance, Inc. to support early-stage drug discovery within CTSI partners: Indiana University, Purdue University, and the University of Notre Dame. The Molecular Therapeutic Program (MTP) will support early-stage drug development studies through services provided by Covance Inc. and Quintiles Biosciences, two contract research organizations that provide pharmaceutical development services. Small grants are now available to help support a list of services available: 

Read More

Three questions with Rich Taylor: Alzheimer's and Brain Awareness Month

Rich Taylor

June is Alzheimer’s and Brain Awareness Month, which seemed a particularly apt time to talk with Rich Taylor, a University of Notre Dame researcher whose research focuses on the discovery and development of new therapeutic leads for the treatment of unmet clinical needs in a number of diseases, including Alzheimer’s. Taylor is associate vice president for research, professor of chemistry and biochemistry and interim director of the Warren Family Research Center for Drug Discovery and Development.

Read More

CO-ADD Offers Antibiotic ESKAPE Screens

The Community forOpen Antimicrobial Drug Discovery (CO-ADD) is a Wellcome Trust funded, non-for-profit, openframework for discovery and development of new therapies against multidrug-resistant (MDR) bacteria (www.co-add.org) based at The University of Queensland in Australia.

CO-ADD will perform primary antibacterial screening for academic research groups as a free service and makes no claims on results or IP.

Read More